AbbVie & Coeptis Therapeutics Holdings

AbbVie: AbbVie Inc. is implicated in the lawsuit for its alleged undisclosed interest in acquiring Coeptis Therapeutics Holdings at a higher price than the secondary offering, which supposedly led to an artificially deflated stock price for Coeptis Therapeutics Holdings.

Coeptis Therapeutics Holdings: Coeptis Therapeutics Holdings is the target of a class action lawsuit alleging that its secondary stock offering and proxy statement omitted material facts regarding AbbVie Inc.'s interest in acquiring it, leading to an artificially deflated stock price.

AbbVie: AbbVie Inc. agreed to acquire Coeptis Therapeutics Holdings for $45 per share, a price significantly higher than Coeptis Therapeutics Holdings's secondary offering price, which is central to the alleged securities fraud.

Coeptis Therapeutics Holdings: Coeptis Therapeutics Holdings is the target of a class action lawsuit alleging securities fraud for omitting material facts regarding AbbVie Inc.'s acquisition interest, which artificially deflated its stock price during an offering.

AbbVie: AbbVie Inc. acquired Coeptis Therapeutics Holdings for $45 per share, an acquisition that was allegedly undisclosed during Coeptis Therapeutics Holdings's secondary stock offering, leading to a windfall for Bain Capital, LP.

Coeptis Therapeutics Holdings: Coeptis Therapeutics Holdings is the primary defendant in the class action lawsuit, accused of making false and misleading statements regarding a secondary stock offering and its subsequent acquisition by AbbVie Inc.